26343, a novel human oxidoreductase and uses therefor
AssigneeMillennium Pharmaceuticals, Inc.
InventorsRachel Meyers, Mark Williamson
Life of this patent
Estimating the term…
Abstract
The invention provides isolated nucleic acids molecules, designated OP nucleic acid molecules, which encode a novel family of oxidoreductase proteins. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing OP nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an OP gene has been introduced or disrupted. The invention still further provides isolated OP proteins, fusion proteins, antigenic peptides, and anti-OP antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
Claims31
An isolated nucleic acid molecule selected from the group consisting of:
- (a) a nucleic acid molecule comprising the nucleotide sequence set forth in SEQ ID NO:1;
- and
- (b) a nucleic acid molecule comprising the nucleotide sequence set forth in SEQ ID NO:3.
An isolated nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence set forth in SEQ ID NO:2.
An isolated nucleic acid molecule comprising the nucleotide sequence contained in the plasmid deposited with ATCC® as Accession Number ______.
An isolated nucleic acid molecule which encodes a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence set forth in SEQ ID NO:2.
An isolated nucleic acid molecule selected from the group consisting of:
- a) a nucleic acid molecule comprising a nucleotide sequence which is at least 90% identical to the nucleotide sequence of SEQ ID NO:1 or 3, or a complement thereof,
- b) a nucleic acid molecule comprising a fragment of at least 15 nucleotides of a nucleic acid comprising the nucleotide sequence of SEQ ID NO:1 or 3, or a complement thereof,
- c) a nucleic acid molecule which encodes a polypeptide comprising an amino acid sequence at least about 90% identical to the amino acid sequence of SEQ ID NO:2;
- and
- d) a nucleic acid molecule which encodes a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, wherein the fragment comprises at least 15 contiguous amino acid residues of the amino acid sequence of SEQ ID NO:2.
An isolated polypeptide selected from the group consisting of:
- a) a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, wherein the fragment comprises at least 15 contiguous amino acids of SEQ ID NO:2;
- b) a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes to a complement of a nucleic acid molecule consisting of SEQ ID NO:1 or 3 under stringent conditions;
- c) a polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 90% identical to a nucleic acid comprising the nucleotide sequence of SEQ ID NO:1 or 3;
- and
- d) a polypeptide comprising an amino acid sequence which is at least 90% identical to the amino acid sequence of SEQ ID NO:2.
A method of identifying a subject having a cellular proliferation, growth, apoptosis, differentiation, and/or migration disorder, or at risk for developing a cellular proliferation, growth, apoptosis, differentiation, and/or migration disorder comprising:
- a) contacting a sample obtained from said subject comprising nucleic acid molecules with a hybridization probe comprising at least 25 contiguous nucleotides of SEQ ID NO:1;
- and
- b) detecting the presence of a nucleic acid molecule in said sample that hybridizes to said probe, thereby identifying a subject having a cellular proliferation, growth, apoptosis, differentiation, and/or migration disorder.
A method of identifying a subject having a cellular proliferation, growth, apoptosis, differentiation, and/or migration disorder, or at risk for developing a cellular proliferation, growth, apoptosis, differentiation, and/or migration disorder comprising:
- a) contacting a sample obtained from said subject comprising nucleic acid molecules with a first and a second amplification primer, said first primer comprising at least 25 contiguous nucleotides of SEQ ID NO:1 and said second primer comprising at least contiguous nucleotides from the complement of SEQ ID NO:1;
- b) incubating said sample under conditions that allow nucleic acid amplification;
- and
- c) detecting the presence of a nucleic acid molecule in said sample that is amplified, thereby identifying a subject having a cellular proliferation, growth, apoptosis, differentiation, and/or migration disorder, or at risk for developing a cellular proliferation, growth, apoptosis, differentiation, and/or migration disorder.
A method of identifying a subject having a cellular proliferation, growth, apoptosis, differentiation, and/or migration disorder, or at risk for developing a cellular proliferation, growth, apoptosis, differentiation, and/or migration disorder comprising:
- a) contacting a sample obtained from said subject comprising polypeptides with an OP binding substance;
- and
- b) detecting the presence of a polypeptide in said sample that binds to said OP binding substance, thereby identifying a subject having a cellular proliferation, growth, apoptosis, differentiation, and/or migration disorder, or at risk for developing a cellular proliferation, growth, apoptosis, differentiation, and/or migration disorder.
A method for identifying a compound capable of treating a cellular proliferation, growth, apoptosis, differentiation, and/or migration disorder characterized by aberrant OP nucleic acid expression or OP polypeptide activity comprising assaying the ability of the compound to modulate OP nucleic acid expression or OP polypeptide activity, thereby identifying a compound capable of treating a cellular proliferation, growth, apoptosis, differentiation, and/or migration disorder characterized by aberrant OP nucleic acid expression or OP polypeptide activity.
A method for treating a subject having a cellular proliferation, growth, apoptosis, differentiation, and/or migration disorder characterized by aberrant OP polypeptide activity or aberrant OP nucleic acid expression comprising administering to the subject an OP modulator, thereby treating said subject having a cellular proliferation, growth, apoptosis, differentiation, and/or migration disorder.
Dependencies are inferred from the claim text.